BUNAVAIL

Peak

buprenorphine hydrochloride; naloxone hydrochloride

NDABUCCALFILM
Approved
Jun 2014
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.

Loss of Exclusivity

LOE Date
Apr 24, 2035
111 months away
Patent Expiry
Apr 24, 2035

Patent Records (4)

Patent #ExpiryTypeUse Code
8147866
Jul 23, 2027
Product
U-1521
9655843
Jul 23, 2027
Product
U-2017
8703177
Aug 20, 2032
Product
—
9522188
Apr 24, 2035
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers